LOS ANGELES, CA / ACCESSWIRE / June 24, 2019 / Compare-autoinsurance.org has launched a new blog post that explains how drivers can save money by bundling multiple policies.

For more info and free car insurance quotes online, visit https://compare-autoinsurance.org/how-can-you-save-money-by-bundling-different-insurance-services/

One of the easiest ways for drivers to save money on car insurance is by bundling different types of policies. Bundling, also called multi-policy discount or multi-line discount, involves acquiring two or more policies from the same insurance company, for example, home insurance and car insurance.

Drivers benefit from the following advantages when they bundle multiple policies at one insurance company:

Get considerable discounts. Drivers that bundle at least three policies, can see their premium drop by 30%. Drivers that bundle only their home insurance and car insurance, will only get a 15% discount on their insurance.
Drivers can save time. By choosing to work with one insurance company, drivers will manage to save time by not having to deal with multiple insurance agents and by paying their bills only once at the same provider.
Drivers will work with one insurance agent. Drivers that choose to work with one insurance company, will have to deal with one insurance agent. This agent will get to know the policyholder and their insurance needs, so they can be properly advised.

For additional info, money-saving tips and free car insurance quotes, visit https://compare-autoinsurance.org/

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

“Bundling policies will help you save time and money”, said Russell Rabichev, Marketing Director of Internet Marketing Company.

Contact: cgurgu@internetmarketingcompany.biz

SOURCE: Internet Marketing Company

ReleaseID: 549668

Atlas Mara Repurchase of Shares and Total Voting Rights Update

TORTOLA / ACCESSWIRE / June 24, 2019 / Atlas Mara Limited (“Atlas Mara” or the “Company” and, including its subsidiaries, the “Group”), the sub-Sahara African financial services group, today announces that on 21 June 2019, the Company repurchased 1,387 shares, all of which were purchased at an average price of $1.45 and will be held as treasury shares.

Atlas Mara repurchased shares pursuant to the authority granted by its Board of Directors, announced in its Q3 2018 Results RNS, to reinstate a lapsed share purchase program. The granted authority is for Atlas Mara to repurchase the Company’s issued share capital up to an aggregate market value equivalent to $10 million by way of its nominated brokers.

As a result of the repurchase of shares, Atlas Mara’s total number of ordinary shares in issue is 174,618,767 of which 1,381,603 are now held in treasury with an additional 3,298,298 ordinary shares held in escrow as part of the contingent consideration for the acquisition of FBZ. Atlas Mara hereby notifies the market that the total number of voting rights in Atlas Mara is 169,938,866. In accordance with rule 5.6.1 of the Financial Conduct Authority’s Disclosure and Transparency Rules (“DTRs”), this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Atlas Mara under the DTRs.

Contact Details

Investors
Kojo Dufu, +1 212 883 4330

Media
Anthony Silverman, +44 (0)7818 036 579

About Atlas Mara

Atlas Mara Limited (LON: ATMA) is a financial services institution founded by Bob Diamond and listed on the London Stock Exchange. With a presence in seven sub-Saharan countries, Atlas Mara aims to be a positive disruptive force in the markets in which we operate by leveraging technology to provide innovative and differentiated product offerings, deliver excellent customer service and accelerate financial inclusion. For more information, visit www.atlasmara.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Atlas Mara

ReleaseID: 549665

Clinical Manifestations of CVI Improved an Average of 46% Across All Five VenoValve Patients

IRVINE, CA / ACCESSWIRE / June 24, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Sunday, June 23, 2019, Dr. Jorge Hernando Ulloa, the Primary Investigator for HJLI’s first-in-human VenoValve study in Bogota, Colombia, reported new and updated data for Hancock Jaffe’s first-in-human VenoValve study at the 2019 C3 Global Conference in Orlando, Florida. Dr. Ulloa’s report indicated that for the first five VenoValve patients, VCSS scores, a measurement of venous disease severity graded by the clinician, have improved an average of forty-six (46%) compared to Pre-VenoValve levels. In addition, Dr. Uolla reported that reflux for the first VenoValve recipient, who is now more than 90 days post VenoValve surgery, has been reduced to a level that is within the range seen in patients without Chronic Venous Insufficiency (“CVI”).

CVI is a condition that occurs when the valves in the veins of the venous system of the leg are injured or destroyed, causing blood to flow backwards. The backwards flow of blood is known as reflux. The VCSS or Venous Clinical Severity Score consists of ten parameters that are used by clinicians to assess venous disease. Both reflux and VCSS are end points in Hancock Jaffe’s first-in-human study.

Dr. Marc H. Glickman, Hancock Jaffe’s Senior Vice President and Chief Medical Officer stated, “With this new 60 day VCSS data, we now have the numbers to support what we have predicted and what we are observing in the clinic: with reductions in reflux, the manifestations of CVI in VenoValve recipients are disappearing. In our first patient, who is now more than 90 days post VenoValve surgery, it is difficult to see any remaining signs of the disease. That patient continued to experience marked improvements between 60 and 90 days post VenoValve surgery, so we are optimistic that we will continue to see improvements in our VenosValve patients.”

On June 7, 2019, Dr. Ulloa presented 30 day data at the Expert Venous Management Conference in Englewood, New Jersey, which indicated that the VenoValve was working in four out of five patients, and that the average reflux reduction across all VenoValve recipients was 45%. The new 60 day VCSS data presented at the C3 Global Conference shows that reductions in reflux are directly correlated to improvements in CVI symptoms, and provides support for HJLI’s contention that even modest reductions in reflux can lead to significant improvements for CVI patients. The reflux reduction data, and the VCSS data, includes one patient where the VenoValve is currently not functioning. That patient has shown modest improvement since the implantation of the VenoValve, and is an important part of the study to show the regulators that the VenoValve does not cause significant harm, even in instances where the VenoValve does not function properly.

The VenoValve is a bioprosthetic replacement for damaged native valves in the deep veins of the leg. HJLI implanted a VenoValve in a sixth patient in early June, which also seems to be functioning properly. Patient six will next be checked approximately 30 days after implantation, pursuant to the study protocol. All patients in the first-in-human trial had severe CVI prior to receiving their VenoValves. In addition, to date there have been no serious device related adverse events associated with the VenoValves.

Robert Berman, Hancock Jaffe’s Chief Executive Officer stated, “I’d like to thank Dr. Ulloa for making the trip from Bogota to Orlando to update the C3 global audience on our latest VenoValve data. It has been a very busy month of June for Hancock Jaffe. In addition to presenting our initial VenoValve data at the Expert Venous Management Conference in New Jersey, and the latest VenoValve data at the C3 Global Conference in Orlando, we raised approximately $3.9 million via a public offering of our common stock, and hired a new Director of Research and Development to assist in preparing the VenoValve for the U.S. pivotal trial. We now have the data, capital, and personnel that we need to advance the VenoValve past several new milestones.”

The next milestones for the VenoValve include: enrollment and implantations for the remaining four patients that will be included in the initial phase of the first-in-human VenoValve study; updated data which is expected to be released in September of 2019; and design verification and validation activities in preparation for the filing of the Investigational Device Exemption (“IDE”) application for the VenoValve U.S. pivotal trial. The September data will include the first VenoValve patient who will be approximately 7 months post VenoValve surgery, patients two through five who will be approximately 5 months post VenoValve surgeries, patient six who will be approximately 3 months post VenoValve surgery, and the remaining four VenoValve recipients who are expected to be between 1 and 3 months post VenoValve surgeries.

The C3 Global Conference draws over one thousand attendees and has been specifically designed for physicians who specialize in interventional cardiology, vascular surgery, and interventional radiology, as well as fellows, residents, and other healthcare professionals interested in atherosclerotic cardiovascular disease. The Venous Summit is a two (2) day course within the C3 Global Conference focusing on venous disease starting from Superficial Venous Disease, Pulmonary Embolism Treatment, DVT, Venous CTO & New Venous Stents. Deep venous CVI afflicts approximately 2.6 million people in the U.S., representing a potential addressable U.S. market of approximately $14 billion. There are currently no effective treatments for deep venous CVI.

About Hancock Jaffe Laboratories, Inc.
Hancock Jaffe Laboratories (NASDAQ: HJLI) specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. Hancock Jaffe currently has two lead product candidates: the VenoValve®, a porcine based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency; and the CoreoGraft®, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery. Hancock Jaffe has a 20-year history of developing and producing FDA approved medical devices that sustain or support life. The current management team at Hancock Jaffe has been associated with over 80 FDA or CE marked medical devices. For more information, please visit HancockJaffe.com.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of Hancock Jaffe Laboratories, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the performance of the new board members described herein) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

HJLI Press Contact:

Amy Carmer
Tel: 949-261-2900
Email: ACarmer@HancockJaffe.com

Media & Investor Relations Contact:

MZ North America
Chris Tyson
Managing Director
(949) 491-8235
HJLI@mzgroup.us
www.mzgroup.us

SOURCE: Hancock Jaffe Laboratories, Inc.

ReleaseID: 549607

SAN CLEMENTE, CA / ACCESSWIRE / June 24, 2019 / Zuggy, Etc. is the brainchild of San Clemente resident, Jennifer Tracy. zuggyetc.com is an online store where you can buy T-Shirts (and even homemade peanut butter balls). So, what’s the big deal about that? Well, Zuggy Etc., is a small little business she started with three of her best friends who happen to be young adult with Autism.

Ali, Isaiah and Juan – are a group of best friends Jennifer has cared for since they were children. Ms Tracy has a background in special needs care and education and spends over 50% of her days with these young men – giving them independence and life outside their homes. One thing the men all have in common when they hang out together – is a love for drawing. Jennifer thought their individual creations were so good – that they would make great T-Shirts. So, she asked them if they would like to start a business and sell their T-shirts and they all said, “Yes!”

SO, Jennifer created Zuggy, Etc., and the boys started churning out drawings each week to find their best work. Jennifer also wanted to teach them about helping others, so every month a new charity is chosen by the young men based on their interests and a portion of the sales goes back to a charity of the kids choice. This month’s chosen charity is, Mavs Foundation, the Dallas Maverick’s Foundation for women, children and families in need, inspired by Ali’s love of basketball.

The website and online store give the three men an ongoing goal each week – coming up with new designs for T-Shirts, engaging and participating in the style and colors of shirts and deciding which charity will benefit from proceeds of shirt sales.

One other activity these three men have enjoyed while spending time with each other and Jennifer – is baking. So, Jennifer also oversees and helps the boys produce a line of homemade peanut butter balls that she sells on the online market, Etsy under Auntie’s Famous Chocolate Covered Peanut Butter Balls, a name the boys gave to their favorite sweets when they were kids. The money earned through sales of their sweet and tasty confections – goes toward outings for the young men who enjoying shopping, traveling and going to the beach. Zuggy, Etc. wants to showcase their great shirts and help with the awareness of autism and the special needs community.

Ali is 22 years old loves basketball; Juan loves shopping and anything with numbers; Isaiah loves the beach and the pool. Jennifer loves spending time with her family and recently founded a charity for special needs named Kahuna Cares Foundation to honor her father famed surfer Terry “Tubesteak” Tracy (the Original ‘Big Kahuna’ from The Gidget movies) who passed away in 2012.

You can look for Zuggy, Etc. on Facebook, Etsy and online at zuggyetc.com.

CONTACT:

949-370-1083

SOURCE: Kahuna Cares Foundation

ReleaseID: 549651

BOCA RATON, FL / ACCESSWIRE / June 24, 2019 / Gregory Fishman, the president and CEO of Resolvly, has been working hard to make debt relief a reality for individuals around the United States. In the last few years, he has been able to transform the company into one of the major leaders for people who are struggling with debt.

Building up for this moment in leading Resolvly is something that took a lot of time. Fishman has worked with a number of successful businesses, and his ability to use some of the skills he learned then for now has really benefited the company.

Fishman early on

Throughout his life, Fishman has been someone who believes in hard work being able to trump everything else. He initially broke into the business world with a chemical manufacturing company. He started out in sales, and later became Vice President of National Interchem.

After many years with the company, he eventually purchased Interchem and continued to grow the company. His rise to the top was definitely a very courageous experience. Starting out as a relatively unknown person, he was able to teach himself in many ways how to properly run a business.

How Interchem led to Resolvly

After spending decades with Interchem, Fishman did not directly jump into Resolvly. He decided to work with another debt relief company in the industry early on called a GHS Solutions. Although he saw a lot of positives in the company, he realized that he wanted to do things a little bit differently. With just a few tweaks, it seemed like Resolvly could be a company that could help to revolutionize the industry. It was intriguing enough for him, and that is why he jumped on the opportunity to start his own company.

Resolvly principles

Hard work as a team was the main focus for Fishman early on when he launch Resolvly. With so many other options out there for people to turn to when they are struggling with that, it makes sense for him to approach things in a very welcoming manner.

Fishman believes that every single person out there wants to work with a company that really treats each client as an individual. Instead of looking at each new person as just another way to make money, every employee is encouraged to develop a relationship and answer questions for clients as much as possible.

In one way or another, Greg Fishman Boca Raton Florida believes that every single person has been in the same situation as a person who is looking for debt relief online. Maybe some employees have actually had those issues in the past. Just needing some type of help or assistance when things are down is something that most people can relate to. By personalizing the experience, Fishman believes that he stands out from the rest with Resolvly.

Future plans with Resolvly

With a number of options for different types of debt relief out there, Resolvly has been able to grow quite a bit in just a few short years. With that being said, Fishman still sees a lot of opportunities for growth. He always wants to find ways to speed up the process, and also make it more hands off for people who need assistance.

Another focus for Fishman in the future is to just have everyone on staff be as knowledgeable as possible on all the different things involving death. A person should know their rights, And they should never feel like they are being harassed. It’s a never ending quest for Fishman to get Resolvly at an even higher level. Going off of his past, he will not be stopping any time soon.

CONTACT:

contact@gregfishman.com

SOURCE: Gregory Fishman

ReleaseID: 549260

ATLANTA, GA / ACCESSWIRE / June 24, 2019 / Strata Worldwide announced the successful completion of a refinancing of its current debt facilities.

The new $69 million credit facilities consist of a $54 million senior secured term loan provided by investment funds managed by Morgan Stanley Private Credit (MSPC), along with a $15 million revolving credit facility from Wells Fargo Capital Finance.

The new credit facilities were put in place to refinance the company’s outstanding indebtedness and will support other general corporate purposes.

Terms of the financing were not disclosed.

Mike Berube, CEO of Strata Worldwide, said, “This financing is a major milestone for Strata and we are excited to continue our partnership with Morgan Stanley Private Credit.”

MSPC portfolio managers Hank D’Alessandro and Ashwin Krishnan added: “We commend Mike Berube and the Strata team on the operating success over the last two years. This refinancing leaves the company with a more flexible capital structure and positions Strata for future success.”

About Strata Worldwide

Strata Worldwide is a global leader in advanced technology solutions to the mining, tunneling and industrial sectors. Strata’s suite of IP-protected electronic products promote a safer, more productive environment demonstrated by a 27-year track record of serving customers with value added products spanning six continents. The company is headquartered in Sandy Springs, GA.

For further information about Strata Worldwide, please visit https://www.strataworldwide.com/.

About Morgan Stanley Private Credit

Morgan Stanley Private Credit, part of Morgan Stanley Investment Management, is a private credit platform focused on direct lending and opportunistic private credit investing in North America and Western Europe. Morgan Stanley Private Credit investment professionals bring significant expertise in origination, structuring and principal investing in the leveraged finance markets.

For further information about Morgan Stanley Private Credit, please visit www.morganstanley.com/im/privatecredit

Media Contact:

Griffin K. Coakley
Phone: 212-761-5504
Email: griffin.coakley@morganstanley.com

SOURCE: Strata Worldwide

ReleaseID: 549655

NEW YORK, NY / ACCESSWIRE / June 24, 2019 / WaykiChain, the leading block chain project which has always been committed to providing solutions to pain points of various industries. A leading case to this, the unprecedented cooperation reached by WaykiChain and CTFEX, a world’s first unicorn investment transfer platform, builds a blockchain based bridge connecting the traditional investors and the crypto market.

What is CTFEX?

CTFEX (Coin Traded Fund Exchange) is the world’s first equity investment transfer platform.

CTFEX devotes to solve the three major pain points in traditional investment industry: high investment thresholds for startups, poor investment liquidity and difficult cross-border investment. CTFEX provides private fund investors with investment opportunity, exit channel and easy access to high-quality unicorn companies. By now, CTFEX has reached cooperation with Jinri Toutiao, Meituan, MINI etc. top-level enterprises with over $70 billion latest market valuation.

Cooperation Model between WaykiChain (WICC) & CTFEX

WaykiChain here to provide CTFEX with advanced blockchain technology to realize the assets cryptomonetization, help global investors get an easy and safe channel to to ensure the authenticity, convenience and security of Investment share transfer from unicorn projects.

WaykiChain, as a leading project in blockchain industry takes the whole industry huge step forward to expand the entire market layout.

Hundreds of Million Flow into Crypto Market?

–Easier Investment, Safer Capital, Higher Profit

The unprecedented investment route provided by CTFEX seeks to achieve the following objectives to varying degrees for participants: growth and preservation of capital. Meanwhile, it provides investors with transparent investment vouchers.

This strategic partnership between WaykiChain and CTFEX establishes the bridge between traditional investors and the cryptocurrency market, general investors and rarest high-threshold investment opportunities, as well as venture investors and safe and transparent investment channels.

The further cooperation with other unicorn companies will allow hundreds of millions of assets flow into the cryptocurrency market, intensively increase the market value, expand the market volume and drive out the revolutionary layout of global traditional investment industry. Moreover, it will be beneficial to broader market layout of blockchain industry and better prospects!

Twitter: https://twitter.com/wayki_chain

Telegram: https://t.me/wiccofficial

Website: https://www.waykichain.com/

PR team: marketing@waykichainhk.com

BD team: biz@waykichainhk.com

Email: marketing@waykichainhk.com

SOURCE: WaykiChain

ReleaseID: 549610